Aquestive Therapeutics, Inc. (AQST) Earnings History
Annual and quarterly earnings data from 2016 to 2025
Loading earnings history...
AQST EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
AQST Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 58.3% | -159.5% | -188.1% |
| 2024 | 69.0% | -53.5% | -76.7% |
| 2023 | 58.8% | -29.9% | -15.6% |
| 2022 | 59.3% | -88.2% | -114.1% |
| 2021 | 70.5% | -68.2% | -138.8% |
Download Data
Export AQST earnings history in CSV or JSON format
Free sign-in required to download data
Aquestive Therapeutics, Inc. (AQST) Earnings Overview
As of May 8, 2026, Aquestive Therapeutics, Inc. (AQST) reported trailing twelve-month net income of -$84M, reflecting -49.0% year-over-year growth. The company earned $-0.69 per diluted share over the past four quarters, with a net profit margin of -188.1%.
Looking at the long-term picture, AQST's historical earnings data spans multiple years. The company achieved its highest annual net income of -$8M in fiscal 2023.
Aquestive Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including DARE (-$17M net income, -41430.9% margin), AYTU (-$24M net income, -20.4% margin), PRAX (-$327M net income), AQST has outperformed on profitability metrics. Compare AQST vs DARE →
AQST Earnings vs Peers
Earnings metrics vs comparable public companies
AQST Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$84M | -89.8% | -$71M | $-0.76 | -188.1% | -159.5% |
| 2024 | -$44M | -460.8% | -$31M | $-0.51 | -76.7% | -53.5% |
| 2023 | -$8M | +85.5% | -$15M | $-0.13 | -15.6% | -29.9% |
| 2022 | -$54M | +22.9% | -$42M | $-1.12 | -114.1% | -88.2% |
| 2021 | -$71M | -26.5% | -$35M | $-1.85 | -138.8% | -68.2% |
| 2020 | -$56M | +15.8% | -$43M | $-1.66 | -121.7% | -93.6% |
| 2019 | -$66M | -7.9% | -$53M | $-2.87 | -125.9% | -100.1% |
| 2018 | -$61M | -586.3% | -$49M | $-2.96 | -91.0% | -72.6% |
| 2017 | -$9M | +6.9% | $-113,000 | $-0.45 | -13.4% | -0.2% |
| 2016 | -$10M | - | $-847,000 | $-0.39 | -18.5% | -1.6% |
See AQST's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AQST Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AQST vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAQST — Frequently Asked Questions
Quick answers to the most common questions about buying AQST stock.
Is AQST growing earnings?
AQST EPS fell to $-0.69, with earnings declining -49.0%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-84M.
What are AQST's profit margins?
Aquestive Therapeutics, Inc. net margin is -188.1%, with operating margin at -159.5%. Below-average margins reflect competitive or cost pressures.
How consistent are AQST's earnings?
AQST earnings data spans 2016-2025. The declining earnings trend is -49.0% YoY. Historical data enables comparison across business cycles.